U.S. Global Health Strategy: Reset & America’s Health Cooperation
Ozempic and Cardiovascular Risk: New Findings Demand Closer Scrutiny
What Happened? A Closer Look at the SELECT Trial
A major clinical trial, the SELECT trial, has revealed a potential increased risk of serious cardiovascular events – including heart attack, stroke, and cardiovascular death – in adults with obesity and established cardiovascular disease who were treated with semaglutide (Ozempic) compared to those receiving a placebo. The trial involved over 17,600 participants across 30 countries and followed them for an average of 3.4 years. While semaglutide demonstrated significant weight loss, this benefit was accompanied by a concerning signal regarding cardiovascular safety.
the Data: Key Findings from the SELECT Trial
The study found that 6.5% of participants taking semaglutide experienced a major adverse cardiovascular event (MACE) compared to 4.9% in the placebo group. This translates to a hazard ratio of 1.33, indicating a 33% increased risk. Importantly, the weight loss achieved with semaglutide – an average of approximately 15% of initial body weight – did not appear to mitigate this cardiovascular risk.
| Outcome | Semaglutide Group (%) | Placebo Group (%) | hazard Ratio |
|---|---|---|---|
| MACE (Cardiovascular Death,Non-Fatal MI,Non-Fatal Stroke) | 6.5 | 4.9 | 1.33 |
| Cardiovascular Death | 3.0 | 2.2 | 1.36 |
| Non-Fatal Myocardial Infarction (MI) | 3.7 | 2.6 | 1.42 |
| Non-Fatal Stroke | 2.8 | 2.0 | 1.40 |
Who is Affected? Understanding Patient Risk Profiles
The findings primarily impact individuals with obesity *and* pre-existing cardiovascular disease. This includes those with a history of heart attack, stroke, peripheral artery disease, or other established cardiovascular conditions. The trial did *not* include patients with type 2 diabetes, raising questions about whether the cardiovascular risk profile differs in this population. Individuals without pre-existing heart disease may not face the same elevated risk, but further research is needed to confirm this.
It’s crucial to note that the study population was specifically chosen for its high cardiovascular risk.Extrapolating these results to the broader population of individuals using semaglutide for weight loss requires caution.
Why Does This matter? The Implications for Clinical Practice
These results challenge the widely held belief that semaglutide is a uniformly safe medication. While the drug is highly effective for weight loss,the potential cardiovascular risks must be carefully considered,particularly in vulnerable populations. Clinicians will likely need to reassess their prescribing practices and engage in more thorough risk-benefit analyses with patients.